The Valley Desk

ArticleJAAD internationalPublished

Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, University of Pennsylvania. Affiliation source

Publication record

Type
Article
Venue
JAAD international
Published
Subject terms
Pharmacovigilance; Hidradenitis Suppurativa; Biologic Agents; Faers Database; Il-17 Inhibitors; Bimekizumab
PubMed ID
41969289
PubMed Central ID
PMC13069420
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal